<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153682</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180391</org_study_id>
    <nct_id>NCT04153682</nct_id>
  </id_info>
  <brief_title>Trial on a Strategy Combining Rapid Diagnostic Testing and Antimicrobial Stewardship to Improve Antibiotic Use in Patients With Hospital-acquired Pneumonia.</brief_title>
  <acronym>SHARP</acronym>
  <official_title>Impact of a Strategy Combining the Rapid Polymerase Chain Reaction Platform FilmArray® and the Intervention of an Antimicrobial Stewardship Team in Hospital-acquired Pneumonia in Non-mechanically Ventilated Patients: a Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hospital-Acquired Pneumonia (HAP) is the second most frequent hospital-acquired infection in
      the US and Europe and accounts for a large proportion of antibiotics prescribed in hospitals.
      Conventional methods to identify causative microorganisms (virus, bacteria) are
      time-consuming and sometimes inaccurate, leading to inadequate treatment in a large
      proportion of HAP patients.

      The FILMARRAY® Pneumonia Panel (FA-PP, bioMérieux) is an automated diagnostic device,
      allowing detection of multiple pathogens and resistance markers in one hour. Strategies
      combining rapid diagnostic testing and intervention of specialists in infectious diseases
      (i.e. antimicrobial stewardship -AMS - experts) showed significant synergistic impact on
      antibiotic use, mortality and costs in bloodstream infections.

      The trial hypothesis is that a strategy combining antimicrobial stewardship and FA-PP
      improves quality of care in HAP patients, as compared to antimicrobial stewardship alone.

      The trial will include patients hospitalized for ≥ 48 hours, aged 18 years or older, who have
      criteria of pneumonia: new lung infiltrate on a chest-x ray, plus evidence that the
      infiltrate is of an infectious origin (i.e. new onset of fever and/or purulent sputum and/or
      leukocytosis and/or decline in oxygenation).

      After informed consent, participants will be randomly allocated to either the intervention or
      the control arm.

      In the control arm, management of HAP patients will include clinical examination and
      conventional microbiological tests. Antibiotic choice will be discussed between AMS experts
      and the physician in charge of the patient.

      In the intervention arm, in addition to the procedures above, the strategy will include rapid
      testing using the FA-PP on a respiratory specimen, obtained by either invasive or
      non-invasive sampling. No additional invasive procedures will be required for the study, and
      FA-PP will be performed on samples collected as part as routine care.

      Investigators will visit the patient at inclusion, on day 3 and on day 30 (or at hospital
      discharge) to collect data on comorbidities, clinical outcomes, results of microbiological
      tests and antibiotics. At the end of follow-up, we will compare the number of days on
      broad-spectrum antibiotics, the incidence of negative outcomes, the length of stay and costs
      in the two arms.

      The use of the FA-PP is expected to prompt early adjustment of antibiotic therapy, improve
      outcomes, decrease length of stay, and to reduce the use of broad-spectrum antibiotics. The
      antibiotic saving may reduce the selection pressure, incidence of colonization with
      multidrug-resistant bacteria and incidence of hospital-acquired superinfections, both at an
      individual and hospital level. Moreover, this trial relies on the intervention of
      multidisciplinary AMS teams that are currently being implemented in many health facilities.
      Their transversal position offers opportunities for recruitment of patients from a wide range
      of medical and surgical departments. This project evaluates the feasibility of clinical
      trials based on the intervention of these teams, and will provide a high level of evidence
      regarding their impact on the prognosis of patients, appropriate use of antibiotics, and
      antimicrobial resistance.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">September 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days on broad-spectrum antibiotics at day 30 or end-of follow-up for 100 patients-days</measure>
    <time_frame>Day 30 or hospital discharge (plus or minus 4 days)</time_frame>
    <description>Number of days that a patient is on an antibiotic, regardless of dose. The list of broad-spectrum antibiotics was defined according to previous literature data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall antibiotic use</measure>
    <time_frame>Day 30 or hospital discharge (plus or minus 4 days)</time_frame>
    <description>Number of days on antibiotics per 100 patient-days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antibiotics for the HAP episode</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Number of days on any antibiotic for the HAP episode</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital length of stay</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Number of days between admission and discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Clostridium difficile colitis</measure>
    <time_frame>Day 30 or hospital discharge (plus or minus 4 days)</time_frame>
    <description>Number of patients with documented Clostridium difficile colitis per 100 patient-days.
Clostridium difficile colitis is defined by clinical evidence of colitis (unexplained and new-onset ≥3 unformed stools) and positive microbiological test relying on the multistep algorithm routinely used in each investigating center and compliant with national and international standards.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical direct costs</measure>
    <time_frame>Day 30 or hospital discharge (plus or minus 4 days)</time_frame>
    <description>Costs of the FILMARRAY® Pneumonia panel (labor and consumables), Antibiotic costs, Total admission costs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analytical performances of the FILMARRAY® Pneumonia panel compared to conventional methods</measure>
    <time_frame>End of the study</time_frame>
    <description>Number of discrepancies on Micro-organism identification and Antibiotic resistance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hospital-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Antimicrobial stewardship (= AMS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Management of HAP according to current practice, including intervention of the AMS team.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antimicrobial Stewardship + Rapid Diagnostic Testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Management of HAP including rapid diagnostic testing (FA-PP) and intervention of the AMS team.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Rapid Diagnostic Testing</intervention_name>
    <description>Automated microbiological diagnostic device based on multiplex PCR analysis, allowing detection of multiple pathogens and resistance markers in one hour from invasive and non-invasive respiratory samples</description>
    <arm_group_label>Antimicrobial Stewardship + Rapid Diagnostic Testing</arm_group_label>
    <other_name>Filmarray® Pneumonia Panel (FA-PP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Antimicrobial stewardship</intervention_name>
    <description>After clinical examination, routine biological tests will be performed. This includes blood culture, direct examination and culture of invasive or noninvasive respiratory samples, urinary antigen tests for Legionella and Pneumococcus, Influenza PCR on nasopharyngeal swabs (during the influenza season).</description>
    <arm_group_label>Antimicrobial Stewardship + Rapid Diagnostic Testing</arm_group_label>
    <arm_group_label>Antimicrobial stewardship (= AMS)</arm_group_label>
    <other_name>AMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient hospitalized for ≥ 48 hours

               -  aged 18 years or older

               -  not mechanically-ventilated at inclusion

               -  with criteria of pneumonia

               -  Dated and signed inform consent

               -  Affiliation with a social security scheme

        Criteria of pneumonia:

          -  New lung infiltrate on a chest-x ray plus

          -  Evidence that the infiltrate is of an infectious origin, i.e. new onset of fever (&gt;
             38.5°C) and/or purulent sputum and/or leukocytosis and/or decline in oxygenation

        Exclusion Criteria:

          -  • Congenital or acquired immunodeficiency: neutropenia (&lt;1 leucocyte/mL or &lt; 0.5
             neutrophil/mL), HIV infection, allograft/autograft of hematopoietic stem cells, solid
             organ transplantation, uptake of immunosuppressive drugs, uptake of corticosteroids
             &gt;10 mg/day equivalent prednisone for a duration ≥15 days before screening

               -  Patients with chronic bronchitis structural changes: very severe COPD (Global
                  initiative for chronic Obstructive Lung Disease GOLD 4), tracheostomy,
                  bronchiectasis, cystic fibrosis

               -  Radiological evidence of thoracic empyema, pulmonary abcess

               -  Moribund patient or death expected from underlying disease during the current
                  admission
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solen Kernéis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antimicrobial Stewardship Team, Hôpitaux Universitaires Paris Centre, Université de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Solen Kernéis, MD, PhD</last_name>
    <phone>+33 1 58.41.19.08</phone>
    <email>solen.kerneis@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillaume Masson, Msc</last_name>
    <phone>+33 1 58 41 34 78</phone>
    <email>guillaume.masson@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaël Lepeule, MD, PhD</last_name>
      <phone>+33145178003</phone>
      <email>raphael.lepeule@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Decousser Jean-Winoc, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charmillon Alexandre, MD</last_name>
      <phone>+33383155536</phone>
      <email>a.charmillon@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Lozniewski Alain, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pilmis Benoît, MD</last_name>
      <phone>+33144128123</phone>
      <email>bpilmis@hpsj.fr</email>
    </contact>
    <investigator>
      <last_name>Le Monnier Alban, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Paris Centre-Site Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solen Kernéis, MD, PhD</last_name>
      <phone>+33 1 58.41.19.08</phone>
      <email>solen.kerneis@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Loubinoux Julien, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Paris Nord Val de Seine-Site Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François-Xavier Lescure, MD, PhD</last_name>
      <phone>+33 140256994</phone>
      <email>xavier.lescure@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Armand-Lefebvre Laurence, PharmD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 1;63(5):e61-e111. doi: 10.1093/cid/ciw353. Epub 2016 Jul 14. Erratum in: Clin Infect Dis. 2017 May 1;64(9):1298. Erratum in: Clin Infect Dis. 2017 Oct 15;65(8):1435. Clin Infect Dis. 2017 Nov 29;65(12):2161.</citation>
    <PMID>27418577</PMID>
  </reference>
  <reference>
    <citation>Messika J, Stoclin A, Bouvard E, Fulgencio JP, Ridel C, Muresan IP, Boffa JJ, Bachmeyer C, Denis M, Gounant V, Esteso A, Loi V, Verdet C, Prigent H, Parrot A, Fartoukh M. The Challenging Diagnosis of Non-Community-Acquired Pneumonia in Non-Mechanically Ventilated Subjects: Value of Microbiological Investigation. Respir Care. 2016 Feb;61(2):225-34. doi: 10.4187/respcare.04143. Epub 2015 Dec 8.</citation>
    <PMID>26647452</PMID>
  </reference>
  <reference>
    <citation>Gadsby NJ, Russell CD, McHugh MP, Mark H, Conway Morris A, Laurenson IF, Hill AT, Templeton KE. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis. 2016 Apr 1;62(7):817-823. doi: 10.1093/cid/civ1214. Epub 2016 Jan 7.</citation>
    <PMID>26747825</PMID>
  </reference>
  <reference>
    <citation>Davey P, Marwick CA, Scott CL, Charani E, McNeil K, Brown E, Gould IM, Ramsay CR, Michie S. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev. 2017 Feb 9;2:CD003543. doi: 10.1002/14651858.CD003543.pub4. Review.</citation>
    <PMID>28178770</PMID>
  </reference>
  <reference>
    <citation>Bookstaver PB, Nimmich EB, Smith TJ 3rd, Justo JA, Kohn J, Hammer KL, Troficanto C, Albrecht HA, Al-Hasan MN. Cumulative Effect of an Antimicrobial Stewardship and Rapid Diagnostic Testing Bundle on Early Streamlining of Antimicrobial Therapy in Gram-Negative Bloodstream Infections. Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00189-17. doi: 10.1128/AAC.00189-17. Print 2017 Sep.</citation>
    <PMID>28630187</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antimicrobial stewardship</keyword>
  <keyword>hospital-acquired pneumonia</keyword>
  <keyword>syndromic approach</keyword>
  <keyword>rapid diagnostic testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Healthcare-Associated Pneumonia</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Anti-Infective Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

